People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness (PALACE)
This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35222
- Alabama (Site ID: 31788)
-
연락하다:
- Heather Logan
- 전화번호: 205-934-6774
- 이메일: heatherlogan@uabmc.edu
-
-
California
-
Los Angeles, California, 미국, 90035
- University of California, Los Angeles CARE Center (Site ID: 601)
-
연락하다:
- Aleen Khodabakhshian
- 전화번호: 310-557-3798
- 이메일: akhodabakhshian@mednet.ucla.edu
-
San Diego, California, 미국, 92103
- UCSD Antiviral Research Center (Site ID: 701)
-
연락하다:
- Dawn Rosenblum
- 전화번호: 619-543-8080
- 이메일: drosenblum@health.ucsd.edu
-
San Francisco, California, 미국, 94110
- University of California, San Francisco (Site ID: 801)
-
연락하다:
- Jay Dwyer
- 전화번호: 415-502-5748
- 이메일: jay.dwyer@ucsf.edu
-
Torrance, California, 미국, 90502-2052
- Harbor University of California Los Angeles Center (Site ID: 603)
-
연락하다:
- Mario Guerrero
- 전화번호: 323-457-1459
- 이메일: mguerrero@lundquist.org
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- University of Colorado Hospital (Site ID: 6101)
-
연락하다:
- Nicola Haakonsen
- 전화번호: 303-724-5931
- 이메일: nicola.haakonsen@cuanschutz.edu
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20032
- Whitman-Walker Institute, Inc. (Site ID: 21791)
-
연락하다:
- Avery Wimpelberg
- 전화번호: 202-797-3589
- 이메일: awimpelberg@whitman-walker.org
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- Northwestern University (Site ID: 2701)
-
연락하다:
- Sherryl L Wolfe
- 전화번호: 312-695-4997
- 이메일: s-wolfe@northwestern.edu
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- Johns Hopkins University (Site ID: 201)
-
연락하다:
- Rebecca L Becker
- 전화번호: 410-614-4036
- 이메일: rbecke22@jhmi.edu
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital (Site ID: 101)
-
연락하다:
- Amy Sbrolla
- 전화번호: 617-726-5598
- 이메일: asbrolla@mgh.harvard.edu
-
Boston, Massachusetts, 미국, 02115
- Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
-
연락하다:
- Hannah Jordan
- 전화번호: 617-732-4785
- 이메일: hcjordan@bwh.harvard.edu
-
-
New Jersey
-
Newark, New Jersey, 미국, 07103
- New Jersey Medical School Clinical Research Center (Site ID: 31786)
-
연락하다:
- Christie Lyn Costanza
- 전화번호: 972-972-9069
- 이메일: costancl@njms.rutgers.edu
-
-
New York
-
New York, New York, 미국, 10010
- Weill Cornell Chelsea (Site ID: 7804)
-
연락하다:
- Mauricio Vergara
- 전화번호: 212-746-7204
- 이메일: mav9177@med.cornell.edu
-
New York, New York, 미국, 10010
- Weill Cornell Uptown (Site ID: 7803)
-
연락하다:
- Keisha Ballentine-Cargill
- 전화번호: 212-746-7804
- 이메일: keb4006@med.cornell.edu
-
New York, New York, 미국, 10032
- Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
-
연락하다:
- Brett T Gray
- 전화번호: 212-305-1570
- 이메일: bg2168@cumc.columbia.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27599-7215
- Chapel Hill (Site ID: 3201)
-
연락하다:
- Erin Elizabeth Hoffman
- 전화번호: 919-843-0720
- 이메일: erin_hoffman@med.unc.edu
-
Greensboro, North Carolina, 미국, 27401-1020
- Greensboro (Site ID: 3203)
-
연락하다:
- Kelly Phillips
- 전화번호: 336-832-7297
- 이메일: kelly.phillips@conehealth.com
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45267-0405
- Cincinnati Clinical Research Site (Site ID: 2401)
-
연락하다:
- Michelle Saemann
- 전화번호: 513-584-2245
- 이메일: saemanmd@ucmail.uc.edu
-
Cleveland, Ohio, 미국, 44106
- Case Clinical Research Site (Site ID: 2501)
-
연락하다:
- Julie Pasternak
- 전화번호: 216-844-2738
- 이메일: pasternak.julie@clevelandactu.org
-
Columbus, Ohio, 미국, 43210
- Ohio State University (Site ID: 2301)
-
연락하다:
- Lindsay Summers
- 전화번호: 614-293-8529
- 이메일: lindsay.summers@osumc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15213
- University of Pittsburgh (Site ID: 1001)
-
연락하다:
- Stacey Edick
- 전화번호: 412-383-1748
- 이메일: edicksm2@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37204
- Vanderbilt Therapeutics (VT) (Site ID: 3652)
-
연락하다:
- Beverly Woodward
- 전화번호: 615-936-8516
- 이메일: beverly.o.woodward@vumc.org
-
-
Texas
-
Houston, Texas, 미국, 77030
- Houston Advancing Research Team (Site ID: 31473)
-
연락하다:
- Maria Laura Martinez
- 전화번호: 713-500-6718
- 이메일: maria.l.martinez@uth.tmc.edu
-
-
Washington
-
Seattle, Washington, 미국, 98104
- University of Washington Positive Research (Site ID: 1401)
-
연락하다:
- Allysson Angeldekao
- 전화번호: 503-715-7324
- 이메일: allysson@uw.edu
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Documented HIV-1 infection
-
Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use
-
HIV-1 RNA >1000 copies/mL within 60 days prior to study entry
-
Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence
-
At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance
-
Adequate laboratory parameters within 60 days prior to study entry:
- Absolute neutrophil count >600/mm3
- Hemoglobin ≥7.0 g/dL
- Platelet count >50,000/μL
- AST and ALT ≤3 × upper limit of normal
- Estimated glomerular filtration rate >15 mL/min/1.73 m²
-
For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry
-
Ability and willingness to provide informed consent
-
Connected to a medical clinic with access to HIV care and antiretroviral therapy
Exclusion Criteria:
- Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
- Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
- Child-Pugh Class C cirrhosis
- No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
- Prior use of lenacapavir
- Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
- Serious medical or psychiatric condition
- Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
- Current pregnancy or breastfeeding
- Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Long-Acting Lenacapavir Plus Long-Acting Cabotegravir
|
Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation. Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses. Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir
기간: Baseline through Week 48
|
Baseline through Week 48
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
기간: Week 48
|
Week 48
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
기간: Week 48
|
Week 48
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
기간: Week 48
|
Week 48
|
|
|
Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir
기간: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance
기간: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir
기간: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
기간: Week 96
|
Week 96
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
기간: Week 96
|
Week 96
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
기간: Week 96
|
Week 96
|
|
|
Percentage of on-time long-acting injections
기간: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir
기간: Baseline through Week 48 and through Week 96
|
Baseline through Week 48 and through Week 96
|
|
|
Plasma trough concentrations of lenacapavir and cabotegravir
기간: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Change in CD4 cell count from baseline
기간: Week 48 and Week 96
|
Week 48 and Week 96
|
|
|
Participant-reported treatment satisfaction
기간: Week 48 and Week 96
|
HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment. |
Week 48 and Week 96
|
|
Change in quality-of-life scores from baseline
기간: Week 48 and Week 96
|
Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life. |
Week 48 and Week 96
|
|
Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline
기간: Week 48 and Week 96
|
Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. |
Week 48 and Week 96
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy
기간: Baseline through Week 48
|
Baseline through Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
기간: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
기간: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
기간: Week 48
|
Week 48
|
공동 작업자 및 조사자
스폰서
스폰서
협력자
협력자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- A5431
- 39159 (기타 식별자: DAIDS-ES ID)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Individual participant data that underlie results in the publication after deidentification
IPD 공유 기간
Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH
IPD 공유 액세스 기준
With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.
For what types of analyses? To achieve aims in the proposal approved by the ACTG.
By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .